Myocardial microstructural and microvascular changes serve as early-phenotype biomarkers in sarcomere mutation carriers prior to the development of overt hypertrophy.
Microstructural alteration and MVD occur in overt HCM and are different in G+ and G- patients. Both also occur in the absence of hypertrophy in sarcomeric mutation carriers, in whom changes are associated with electrocardiographic abnormalities. Measurable changes in myocardial microstructure and microvascular function are early-phenotype biomarkers in the emerging era of disease-modifying therapy.
Joy et al. (Tue,) studied this question.